 This trial is designed to investigate the safety, dosing schedule, and efficacy of the combination treatment of Panobinostat a histone deacetylase inhibitor and hormone therapy for recurrent prostate cancer. This trial is at its Phase II stage. As of July 23, 2013 Arm B was closed to accrual, all the remaining slots in accrual will be allocated to Arm A. 